DOCSLIB.ORG

Injectable Medication Hcpcs/Dofr Crosswalk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Injectable Medication Hcpcs/Dofr Crosswalk INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK HCPCS DRUG NAME GENERIC NAME PRIMARY CATEGORY SECONDARY CATEGORY J0287 ABELCET Amphotericin B lipid complex THERAPEUTIC INJ HOME HEALTH/INFUSION** J0400 ABILIFY Aripiprazole, intramuscular, 0.25 mg THERAPEUTIC INJ J0401 ABILIFY MAINTENA Apriprazole 300mg, IM injection THERAPEUTIC INJ J9264 ABRAXANE paclitaxel protein-bound particles, 1 mg J1120 ACETAZOLAMIDE SODIUM Acetazolamide sodium injection THERAPEUTIC INJ J0132 ACETYLCYSTEINE INJ Acetylcysteine injection, 10 mg THERAPEUTIC INJ ACTEMRA 162mg/0.9ml Syringe (50242- J3262 SELF-INJECTABLE 0138-01) Tocilizumab, 1 mg ACTEMRA INJECTION (50242-0136-01, J3262 50242-0137-01) Tocilizumab 200mg, 400mg THERAPEUTIC INJ J0800 ACTHAR HP Corticotropin injection THERAPEUTIC INJ Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4- 90648 ACTHIB dose schedule), for intramuscular use THERAPEUTIC INJ IMMUNIZATIONS J0795 ACTHREL Corticorelin ovine triflutal THERAPEUTIC INJ J9216 ACTIMMUNE Interferon gamma 1-b 3 miillion units SELF-INJECTABLE CHEMO ADJUNCT* J2997 ACTIVASE Alteplase recombinant, 1mg THERAPEUTIC INJ HOME HEALTH/INFUSION** J0133 ACYCLOVIR SODIUM Acyclovir, 5 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** 90715 ADACEL Tdap vaccine, > 7 yrs, IM THERAPEUTIC INJ IMMUNIZATIONS J2504 ADAGEN Pegademase bovine, 25 IU THERAPEUTIC INJ HOME HEALTH/INFUSION** J9042 ADCETRIS Brentuximab vedotin Injection THERAPEUTIC INJ CHEMOTHERAPY J0153 ADENOCARD Adenosine 6 MG THERAPEUTIC INJ J0171 ADRENALIN Adrenalin (epinephrine) inject THERAPEUTIC INJ J9000 ADRIAMYCIN Doxorubicin hcl 10 MG THERAPEUTIC INJ CHEMOTHERAPY J9190 ADRUCIL Fluorouracil injection, 500 mg THERAPEUTIC INJ CHEMOTHERAPY Factor VIII (antihemophilic factor, recombinant) per IU, not BLOOD/BLOOD PRODUCTS FOR J7192 ADVATE otherwise specified THERAPEUTIC INJ HEMOPHILIA Antihemophilic Factor (Recombinant), PEGylated, is a BLOOD/BLOOD PRODUCTS FOR ADYNOVATE THERAPEUTIC INJ C9137 human antihemophilic factor HEMOPHILIA Influenza virus vaccine, split virus, preservative free, when administered to individuals 3 years and older, for 90656 AFLURIA PRESERVATIVE FREE SUSP intramuscular use (Code Price is per 0.5 mL dose) (Please note: Agriflu is only indicated for use in patients 18 years of age and older) THERAPEUTIC INJ IMMUNIZATIONS Influenza virus vaccine, split virus, when administered to 90658 AFLURIA SUSP individuals 3 years of age and older, for intramuscular use (Code price is per 0.5 mL based on Fluzone for patients 3 through 17 years old) (For patients 18 years old and older. THERAPEUTIC INJ IMMUNIZATIONS Influenza virus vaccine, split virus, when administered to Q2035 AFLURIA SUSP individuals 3 years of age and older, for intramuscular use (Afluria) see also 90656 and 90658 THERAPEUTIC INJ IMMUNIZATIONS BLOOD/BLOOD PRODUCTS FOR Factor VIII (antihemophilic factor, recombinant, single chain) THERAPEUTIC INJ J7199 AFSTYLA HEMOPHILIA J3246 AGGRASTAT Tirofiban HCl, 0.25 mg THERAPEUTIC INJ Q2034 AGRIFLU Influenza virus vaccine, split virus, for intramuscular use THERAPEUTIC INJ IMMUNIZATIONS J1720 A-HYDROCORT Hydrocortisone sodium succinate THERAPEUTIC INJ CHEMO ADJUNCT* J0190 AKINETON Biperiden lactate, per 5 mg THERAPEUTIC INJ J1931 ALDURAZYME Laronidase injection THERAPEUTIC INJ HOME HEALTH/INFUSION** J9215 ALFERON N Interferon alfa-N3 (human leukocyte derived), 250,000 IU inj SELF-INJECTABLE CHEMO ADJUNCT* * If associated with a cancer Dx ICD‐9 Rev.7/12/16 ** When administered by a nurse in a home setting 1 of 28 Effective 10/18/16 INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK HCPCS DRUG NAME GENERIC NAME PRIMARY CATEGORY SECONDARY CATEGORY J9305 ALIMTA Pemetrexed, 10 mg THERAPEUTIC INJ CHEMOTHERAPY J9245 ALKERAN Melphalan hydrochl 50 MG THERAPEUTIC INJ CHEMOTHERAPY J2469 ALOXI Palonosetron HCl, 25 mcg THERAPEUTIC INJ CHEMO ADJUNCT* BLOOD/BLOOD PRODUCTS FOR J7190 ALPHANATE Factor VIII (antihemophilic Factor [human]) per IU THERAPEUTIC INJ HEMOPHILIA Von Willebrand Factor complex, human, ristocetin coFactor BLOOD/BLOOD PRODUCTS FOR J7186 ALPHANATE VWF (not otherwise specified ), per I.U. THERAPEUTIC INJ HEMOPHILIA Factor IX (antihemophilic Factor, purified, non-recombinant) BLOOD/BLOOD PRODUCTS FOR J7193 ALPHANINE SD per IU THERAPEUTIC INJ HEMOPHILIA Coagulation Factor IX (Recombinant), Fc Fusion Protein], BLOOD/BLOOD PRODUCTS FOR J7201 ALPROLIX THERAPEUTIC INJ Lyophilized Powder for Solution for Intravenous Injection HEMOPHILIA Injection, alprostadil, 1.25 mcg (code may be used for J0270 Alprostadil 500 Medicare when drug administered under direct physician supervision, not for use when drug is self-administered) SELF-INJECTABLE J0289 AMBISOME Amphotericin B liposome inj THERAPEUTIC INJ HOME HEALTH/INFUSION** J2920 A-METHAPRED Methylprednisolone injection THERAPEUTIC INJ CHEMO ADJUNCT* J2930 A-METHAPRED Methylprednisolone injection THERAPEUTIC INJ CHEMO ADJUNCT* J0215 AMEVIVE Alefacept THERAPEUTIC INJ S0017 AMICAR Aminocaproic acid THERAPEUTIC INJ AMIKACIN SULF INJ USP 1GRAM/4ML J0278 FLIPTOP VIAL Amikacin sulfate injection THERAPEUTIC INJ HOME HEALTH/INFUSION** J0278 AMIKIN Amikacin sulfate injection THERAPEUTIC INJ HOME HEALTH/INFUSION** J0280 AMINOPHYLLINE Aminophyllin 250 MG inj THERAPEUTIC INJ HOME HEALTH/INFUSION** J0282 AMIODARONE HCL Amiodarone hcl THERAPEUTIC INJ J3470 AMPHADASE 150 UNIT/ML SOLN Hyaluronidase, up to 150 units THERAPEUTIC INJ J0285 AMPHOCIN Amphotericin B THERAPEUTIC INJ HOME HEALTH/INFUSION** J0288 AMPHOTEC Ampho b cholesteryl sulfate THERAPEUTIC INJ HOME HEALTH/INFUSION** J0285 AMPHOTERICIN B Amphotericin B THERAPEUTIC INJ HOME HEALTH/INFUSION** J0290 AMPICILLIN SODIUM Ampicillin 500 MG inj THERAPEUTIC INJ HOME HEALTH/INFUSION** J0295 AMPICILLIN-SULBACTAM Ampicillin sodium per 1.5 gm THERAPEUTIC INJ HOME HEALTH/INFUSION** J0300 AMYTAL SODIUM Amobarbital 125 MG inj THERAPEUTIC INJ J0716 ANASCORP Centruroides immune f(ab)2, up to 120 milligrams THERAPEUTIC INJ J0690 ANCEF Cefazolin sodium injection THERAPEUTIC INJ HOME HEALTH/INFUSION** J0330 ANECTINE Succinycholine chloride inj THERAPEUTIC INJ J0583 ANGIOMAX Bivalirudin, 1mg THERAPEUTIC INJ 90581 ANTHRAX VACCINE Anthrax vaccine, sc THERAPEUTIC INJ IMMUNIZATIONS J1451 ANTIZOL Fomepizole, 15 mg THERAPEUTIC INJ J1260 ANZEMET Dolasetron mesylate THERAPEUTIC INJ CHEMO ADJUNCT* J0364 APOKYN Apomorphine hydrochloride, 1mg SELF-INJECTABLE J3430 AQUA-MEPHYTON Vitamin K phytonadione inj THERAPEUTIC INJ J0256 ARALAST Alpha 1 proteinase inhibitor THERAPEUTIC INJ HOME HEALTH/INFUSION** J0390 ARALEN Chloroquine injection THERAPEUTIC INJ J0380 ARAMINE Metaraminol bitartrate THERAPEUTIC INJ J0881 ARANESP Darbepoetin alfa, 1 microgram (non-ESRD use) SELF-INJECTABLE CHEMO ADJUNCT* J0882 ARANESP Darbepoetin alfa, 1 microgram (for ESRD on dialysis SELF-INJECTABLE CHEMO ADJUNCT* J2793 ARCALYST Rilonacept Injection 220 mg Solr SELF-INJECTABLE J2430 AREDIA Pamidronate disodium /30 MG THERAPEUTIC INJ CHEMO ADJUNCT* C9121 ARGATROBAN 100 MG/ML SOLN Argatroban, Per 5 mg THERAPEUTIC INJ C9138 ARISTADA Ariprprazole lauroxilextended release suspension THERAPEUTIC INJ J3302 ARISTOCORT FORTE Triamcinolone diacetate inj THERAPEUTIC INJ * If associated with a cancer Dx ICD‐9 Rev.7/12/16 ** When administered by a nurse in a home setting 2 of 28 Effective 10/18/16 INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK HCPCS DRUG NAME GENERIC NAME PRIMARY CATEGORY SECONDARY CATEGORY J3303 ARISTOSPAN INTRA-ARTICULAR Triamcinolone hexacetonl inj THERAPEUTIC INJ J3303 ARISTOSPAN INTRALESIONAL Triamcinolone hexacetonl inj THERAPEUTIC INJ J1652 ARIXTRA Fondaparinux sodium, 0.5 mg SELF-INJECTABLE J9261 ARRANON 5 MG/ML SOLN Nelarabine, 50 Mg THERAPEUTIC INJ CHEMOTHERAPY J9302 ARZERRA Ofatumumab THERAPEUTIC INJ CHEMOTHERAPY C9399, J3490 ASCLERA Polidocanol Injection THERAPEUTIC INJ J2275 ASTRAMORPH Morphine sulfate injection THERAPEUTIC INJ HOME HEALTH/INFUSION** Lymphocyte immune globulin, antithymocyte globulin, J7504 ATGAM equine, parenteral, 250 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** J2060 ATIVAN Lorazepam injection THERAPEUTIC INJ J0461 ATROPINE SULFATE Atropine sulfate injection THERAPEUTIC INJ Antithrombin (Recombinant) BLOOD/BLOOD PRODUCTS FOR J7196 ATRYN Lyophilized THERAPEUTIC INJ HEMOPHILIA 90705 ATTENUVAX Measles vaccine, SC THERAPEUTIC INJ IMMUNIZATIONS C9257 AVASTIN Bevacizumab, 0.25 mg THERAPEUTIC INJ CHEMOTHERAPY J9035 AVASTIN Bevacizumab injection, 10 mg THERAPEUTIC INJ CHEMOTHERAPY J3145 AVEED Testosterone undecanoate 250 mg/ml THERAPEUTIC INJ J2280 AVELOX Moxifloxacin 100 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** Interferon beta-1A, 11 mcg for intramuscular use (See also Q3025 AVONEX J1825) SELF-INJECTABLE Q3027 AVONEX Interferon beta-1a, 33 mcg SELF-INJECTABLE J0714 AVYCAZ Ceftazidime-avibactam Injection THERAPEUTIC INJ S0073 AZACTAM Aztreonam, 500 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** J7501 AZATHIOPRINE SODIUM Azathioprine parenteral THERAPEUTIC INJ TRANSPLANT* J0475 BACLOFEN Baclofen 10 MG injection THERAPEUTIC INJ J2700 BACTOCILL IN DEXTROSE Oxacillin sodium injeciton THERAPEUTIC INJ HOME HEALTH/INFUSION** J0470 BAL IN OIL Dimecaprol injection THERAPEUTIC INJ Hepatitis B Immune Globulin (HBIg), human, for 90371 BAYHEP B intramuscular use (Note: For billing HepaGam B use Q4090 for IM use and 90399 for IV use) THERAPEUTIC INJ Rabies Immune Globulin (R IG), human, for intramuscular 90375 BAYRAB and/or subcutaneous use THERAPEUTIC INJ 90385 BAYRHO-D Rh IG, minidose, IM THERAPEUTIC INJ J2788 BAYRHO-D Rho d immune globulin, human, minidose, 50 mcg (250 iu) THERAPEUTIC INJ J2790 BAYRHO-D Rho d immune globulin, human, minidose, 300 mcg (1500 iu) THERAPEUTIC
Load more

Recommended publications
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Pharmacokinetic Profile of Defibrotide in Patients with Renal Impairment
    Journal name: Drug Design, Development and Therapy Article Designation: Clinical Trial Report Year: 2016 Volume: 10 Drug Design, Development and Therapy Dovepress Running head verso: Tocchetti et al Running head recto: Pharmacokinetic profile of defibrotide in renal impairment open access to scientific and medical research DOI: http://dx.doi.org/10.2147/DDDT.S112181 Open Access Full Text Article CLINICAL TRIAL REPORT Pharmacokinetic profile of defibrotide in patients with renal impairment Paola Tocchetti1 Abstract: Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/ Elena Tudone2 SOS), is an unpredictable, potentially life-threatening complication of hematopoietic stem cell Jean-Francois Marier3 transplant conditioning. Severe VOD/SOS, generally associated with multiorgan dysfunction Thomas C Marbury4 (pulmonary or renal dysfunction), may be associated with .80% mortality. Defibrotide, recently Katie Zomorodi5 approved in the US, has demonstrated efficacy treating hepatic VOD/SOS with multiorgan Mark Eller6 dysfunction. Because renal impairment is prevalent in patients with VOD/SOS, this Phase I, open-label, two-part study in adults examined the effects of hemodialysis and severe or end-stage 1 2 Gentium, Clinical Operations, renal disease (ESRD) on defibrotide pharmacokinetics (PK). Part 1 compared defibrotide PK Gentium, Villa Guardia, Como, Italy; 3Reporting and Analysis Services, during single 6.25 mg/kg doses infused with and without dialysis. Part 2 assessed defibrotide Pharsight, a Certara Company, plasma PK after multiple 6.25 mg/kg doses in nondialysis-dependent subjects with severe/ Montreal, Quebec, Canada; 4Orlando ESRD versus healthy matching subjects. Among six subjects enrolled in Part 1, percent ratios Clinical Research Center, Orlando, FL, 5 For personal use only.
    [Show full text]
  • Tracking Form for Applicants for New Technology Add-On Payments Under the Acute Inpatient Prospective Payment System (IPPS) for Federal Fiscal Year (FY) 2017
    Centers for Medicare & Medicaid Services Center for Medicare Management 7500 Security Boulevard Baltimore, Maryland 21244-1850 Tracking Form for Applicants for New Technology Add-on Payments under the Acute Inpatient Prospective Payment System (IPPS) for Federal Fiscal Year (FY) 2017 1. Technology Name: Titan Spine Endoskeleton® nanoLOCK™ Interbody Device 2. Manufacturer Name: Titan Spine 3. Trade Brand of Technology: Titan Spine Endoskeleton® nanoLOCK™ 4. Brief Description of Service, Device or Drug: The nanoLOCK™ is a nanotechnology-based interbody medical device with a dual acid-etched titanium interbody system to treat patients with degenerative disc disease. One of the key distinguishing features is the surface manufacturing technique and materials which produce macro, micro, and nano surface textures. The unique combination of surface topographies enable initial implant fixation, mimic an osteoclastic pit for bone growth, and especially produce the nano­ scale features that interface with the integrins on the outside of the cellular membrane. These generate better osteogenic and angiogenic responses that enhance bone growth, fusion and stability. nanoLOCK™’s clinical features also reduce pain, improve recovery time, lower rates of device complications such as debris and inflammation. Centers for Medicare & Medicaid Services Center for Medicare Management 7500 Security Boulevard Baltimore, Maryland 21244-1850 Tracking Form for Applicants for New Technology Add-on Payments under the Acute Inpatient Prospective Payment System (IPPS) for Federal Fiscal Year (FY) 2017 1. Technology Name: defibrotide 2. Manufacturer Name: Jazz Pharmaceuticals, Inc. 3. Trade Brand of Technology: Defitelio®. The trade brand name of Defitelio for defibrotide has been conditionally approved by the United States (US) Food and Drug Administration (FDA) and is subject to FDA confirmation in connection with approval of the New Drug Application (NDA).
    [Show full text]
  • Defibrotide for the Treatment and Prophylaxis of Hepatic Veno-Occlusive Disease
    Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease Systematic Review Decision Support Document No. 84 ISSN online: 1998-0469 Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease Systematic Review Vienna, March 2015 Project Team Project Leader: Dr. med. Anna Nachtnebel, MSc Authors: Dr. med. Eleen Rothschedl Dr. med. Anna Nachtnebel, MSc Internal Review: Dr. rer.nat. Agnes Kisser Project Support Systematic Literature Search: Tarquin Mittermayr, BA External Review: Prof. Dr. med. Wolfgang Bethge Medizinische Universitätsklinik II Hämatologie/Onkologie Allogene Stammzelltransplantation Universitätsklinikum Tübingen Correspondence Dr. med. Eleen Rothschedl, e-mail: [email protected] This report should be referenced as follows: Rothschedl E., Nachtnebel A. Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document No. 84; 2015. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment. Conflict of interest All authors and reviewers involved in the production of this report have declared they have no conflicts of interest in relation to the technology assessed according to the Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org). Commissioned by the Austrian Ministry of Health, this report systematically assessed the intervention described herein as decision support for the inclusion in the catalogue of benefits. CONTENT INFORMATION Publisher: Ludwig Boltzmann Gesellschaft GmbH Nußdorferstr. 64, 6 Stock, A-1090 Wien http://www.lbg.ac.at/de/lbg/impressum Responsible for content: Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) Garnisongasse 7/20, A-1090 Vienna http://hta.lbg.ac.at/ Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize the research results of the Ludwig Boltzmann Institute of Health Technology Assessments.
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • Antiplatelet Agents for Chronic Kidney Disease
    bs_bs_banner Nephrology 18 (2013) 474–476 COCHRANE COMMENTARIES Edited by Angela Webster ([email protected]) Written by Suetonia Palmer, Valeria Saglimbene and Giovanni FM Strippoli ([email protected]) Antiplatelet agents for chronic kidney disease What is in this review about? patients) were conducted in people who had an acute coro- nary syndrome or who were undergoing percutaneous inter- This systematic review summarized the randomized trials vention and examined glycoprotein IIb/IIIa inhibitors evaluating the benefits and harms of antiplatelet agents (abciximab, tirofiban or eptifibatide) with or without clopi- (including aspirin, dipyridamole, thienopyridines (clopidog- dogrel in addition to aspirin and heparin in the setting of rel, ticlopidine), defibrotide, picotamide, sulfinpyrazone, and chronic kidney disease stage 3–5. For these interventions, glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban and data were entirely based on post-hoc analysis for the sub- eptifibatide)) in addition to standard treatment in people group with chronic kidney disease derived from larger trials. who have chronic kidney disease. We focus here on evidence The remaining trials examined oral antiplatelet therapy in of major cardiovascular events, mortality and bleeding. people who have chronic kidney disease (aspirin, thienopy- ridines or dipyridamole, defibrotide, picotamide, or sulfin- What are the key findings? pyrazone alone or in combination) and who were at risk of or who had stable cardiovascular disease. Overall, 19 studies In
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • CPT / HCPCS Code Drug Description Approximate Cost Share
    The information listed here is for our most prevalent plan. The amount you pay for a covered drug will depend on your plan’s coverage. Please refer to your Medical Plan GTB for more information. To find out the cost of your drugs, please contact HMSA Customer Service at 1-800-776-4672. If you receive services from a nonparticipating provider, you are responsible for a copayment plus any difference between the actual charge and the eligible charge. Legend $0 = no cost share $ = $100 and under $$ = over $100 to $250 $$$ = over $250 to $500 $$$$ = over $500 to $1000 $$$$$ = over $1000 1 = Please call HMSA Customer Service 1-800-776-4672 for cost share information. 2 = The cost share for this drug is dependent upon the diagnosis. Please call HMSA Customer Service at 1-800-772-4672 for more information. 3 = Cost share information for these drugs is dependent upon the dose prescribed. Please call HMSA Customer Service at 1- 800-772-4672 for more information. CPT / HCPCS approximate Code Drug Description cost share J0129 Abatacept Injection $$$$ J0130 Abciximab Injection 3 J0131 Acetaminophen Injection $ J0132 Acetylcysteine Injection $ J0133 Acyclovir Injection $ J0135 Adalimumab Injection $$$$ J0153 Adenosine Inj 1Mg $ J0171 Adrenalin Epinephrine Inject $ J0178 Aflibercept Injection $$$ J0180 Agalsidase Beta Injection 3 J0200 Alatrofloxacin Mesylate 3 J0205 Alglucerase Injection 3 J0207 Amifostine 3 J0210 Methyldopate Hcl Injection 3 J0215 Alefacept 3 J0220 Alglucosidase Alfa Injection 3 J0221 Lumizyme Injection 3 J0256 Alpha 1 Proteinase Inhibitor
    [Show full text]
  • Canine Pemphigus Vulgaris Treated with Gold Salt Therapy
    CASE REPORT Canine Pemphigus Vulgaris Treated with Gold Salt Therapy G.P. OLYNYK AND B.J. GUTHRIE Edgemont Veterinary Clinic, #12, 34 Edgedale Drive North West, Calgary, Alberta T3A 2R4 Summary treated with antibiotics, prednisone, euthanasia, gold salt therapy, or A nine year old spayed female Collie vitamins and metronidazole with no further antibiotic-corticosteroid treat- was diagnosed as having pemphigus lasting or dramatic improvement. The ments with the owner. vulgaris. Response to corticosteroid dog had previously been diagnosed as On May 13, 1982 we initiated auro- and antibiotic therapies was unsatis- having hip dysplasia and secondary thioglucose3 therapy as outlined pre- factory. Aurothioglucose therapy was arthritis. viously (1). Two intramuscular injec- used later as the sole treatment. The tions of 5.0 and 10.0 mg were given as dog achieved a complete remission Clinical Findings and Treatment tests of tolerance on May 13 and 20 lasting at least ten months. At first presentation, the physical respectively. The therapeutic series examination was unremarkable with involved six weekly intramuscular Resumme' the exception of skin lesions. The injections at 1.0 mg/kg. These injec- Traitement du pemphigus vulgaire refractory nature and the location and tions were given May 27, June 3, 10, canin avec de l'aurothioglucose nature of the lesions suggested a diag- 17, 24 and 30. No other therapy was Les auteurs ont diagnostique la nosis of pemphigus vulgaris. used. A physical examination, weigh- pemphigus vulgaire, chez une chienne A biopsy was obtained; the resulting in and discussion with the owner Collie castree et agee de neuf ans.
    [Show full text]
  • Cumulative Cross Index to Iarc Monographs
    PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13,
    [Show full text]